Genetic influences on smoking and clinical disease: Understanding behavioral and biological pathways with mediation analysis

Annals of the American Thoracic Society

Volumn 11, Issue 7, 2014, Pages 1082-1083

  Lutz, Sharon M ^a   Hokanson, John E ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; COTININE; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; NICOTINE; TOBACCO SMOKE;

CHROMOSOME 15Q; CHROMOSOME 8P; CHRONIC OBSTRUCTIVE LUNG DISEASE; EDITORIAL; ENVIRONMENTAL EXPOSURE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE POLICY; HEREDITY; HUMAN; LUNG CANCER; METABOLISM; MORTALITY; NICOTINE REPLACEMENT THERAPY; PHENOTYPE; SMOKING; SMOKING CESSATION; SMOKING CESSATION PROGRAM; TOBACCO DEPENDENCE; TOBACCO USE; CLINICAL PATHWAY; COMPREHENSION; FEMALE; GENETIC PREDISPOSITION; GENETICS; HEALTH BEHAVIOR; INTERPERSONAL COMMUNICATION; LUNG NEOPLASMS; MALE; PROCEDURES; PSYCHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; THERAPY; UNITED STATES;

COMPREHENSION; CRITICAL PATHWAYS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HEALTH BEHAVIOR; HUMANS; LUNG NEOPLASMS; MALE; NEGOTIATING; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; SMOKING CESSATION; UNITED STATES;

EID: 84911931171     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201407-315ED     Document Type: Editorial

References (16)

1. The Health Consequences of Smoking - 50 Years of Progress. A Report of the Surgeon General [Internet]. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; Available from: http://www.surgeongeneral.gov/library/reports/50-years-of-progress/
2. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, Manolescu A, Thorleifsson G, Stefansson H, Ingason A, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008;452:638-642.
3. Loukola A, Hällfors J, Korhonen T, Kaprio J. Genetics and smoking. Curr Addict Rep 2014;1:75-82.
4. Bloom AJ, Hartz SM, Baker TB, Chen LS, Piper ME, Fox L, Martinez M, Hatsukami D, Johnson EO, Laurie CC, et al. Beyond cigarettes-perday: a genome-wide association study of the biomarker carbon monoxide. Ann Am Thorac Soc 2014;11:1003-1010.
5. Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, Feng S, Hersh CP, Bakke P, Gulsvik A, et al.; ICGN Investigators. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 2009;5:e1000421.
6. Vanderweele TJ, Vansteelandt S. Odds ratios for mediation analysis for a dichotomous outcome. Am J Epidemiol 2010;172:1339-1348.
7. VanderWeele TJ, Vansteelandt S. Mediation analysis with multiple mediators. Epidemiologic Methods 2013;2:95-115.
8. Committee on Passive Smoking, Board of Environmental Studies and Toxicology, National Research Council. Environmental tobacco smoke: measuring exposures and assessing health effects [Internet]. Washington, DC: National Academy Press; 1986. Available from: http://www.nap.edu/openbook.php?isbn=0309037301
9. Benowitz NL. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol Rev 1996;18:188-204.
10. St Helen G, Novalen M, Heitjan DF, Dempsey D, Jacob P III, Aziziyeh A, Wing VC, George TP, Tyndale RF, Benowitz NL. Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiol Biomarkers Prev 2012;21:1105-1114.
11. Siedlinski M, Tingley D, Lipman PJ, Cho MH, Litonjua AA, Sparrow D, Bakke P, Gulsvik A, Lomas DA, Anderson W, et al.; COPDGene and ECLIPSE Investigators. Dissecting direct and indirect genetic effects on chronic obstructive pulmonary disease (COPD) susceptibility. Hum Genet 2013;132:431-441.
12. VanderWeele TJ, Asomaning K, Tchetgen Tchetgen EJ, Han Y, Spitz MR, Shete S, Wu X, Gaborieau V, Wang Y, McLaughlin J, et al. Genetic variants on 15q25.1, smoking, and lung cancer: an assessment of mediation and interaction. Am J Epidemiol 2012;175:1013-1020.
13. Wang Y, Broderick P, Matakidou A, Eisen T, Houlston RS. Chromosome 15q25 (CHRNA3-CHRNA5) variation impacts indirectly on lung cancer risk. PLoS ONE 2011;6:e19085.
14. Wang J, Spitz MR, Amos CI, Wu X, Wetter DW, Cinciripini PM, Shete S. Method for evaluating multiple mediators: mediating effects of smoking and COPD on the association between the CHRNA5-A3 variant and lung cancer risk. PLoS ONE 2012;7:e47705.
15. Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, Liu J, Lee W, Edlund CK, Hall S, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet Genomics 2013;23:94-103.
16. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86:1119-1127.